Frontiers in Anti-Infective Drug Discovery.:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Sharjah :
Bentham Science Publishers,
2018.
|
| Schriftenreihe: | Frontiers in Anti-Infective Drug Discovery Ser.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | Protein Synthesis Inhibition. |
| Beschreibung: | 1 online resource (293 pages) |
| ISBN: | 9781681085623 1681085623 |
Internformat
MARC
| LEADER | 00000cam a2200000Mu 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1041918857 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr |n|---||||| | ||
| 008 | 180623s2018 xx o 000 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d OCLCQ |d K6U |d OCLCO |d OCLCF |d YDX |d N$T |d UKAHL |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 066 | |c (S | ||
| 019 | |a 1040624054 |a 1264792542 | ||
| 020 | |a 9781681085623 | ||
| 020 | |a 1681085623 | ||
| 035 | |a (OCoLC)1041918857 |z (OCoLC)1040624054 |z (OCoLC)1264792542 | ||
| 050 | 4 | |a RM267 | |
| 082 | 7 | |a 616.9/0461 |2 23 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Atta-ur-Rehman. | |
| 245 | 1 | 0 | |a Frontiers in Anti-Infective Drug Discovery. |
| 260 | |a Sharjah : |b Bentham Science Publishers, |c 2018. | ||
| 300 | |a 1 online resource (293 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Frontiers in Anti-Infective Drug Discovery Ser. ; |v v. 7 | |
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |6 880-01 |a Intro; CONTENTS; PREFACE; List of Contributors; The Role of the Microbiota in the Genesis of Gastrointestinal Cancers; Edda Russo and Amedeo Amedei*; 1. INTRODUCTION; 2. THE HUMAN MICROBIOTA; 3. THE GASTROINTESTINAL MICROBIOTA; 3.1. Composition and Activities; 3.2. Gastro-Intestinal Colonization by the Microbiota and Selection; 3.3. The Human Microbiome Project; 3.4. Gut Enterotypes; 4. THE ROLE OF MICROBIOTA IN TUMOR DEVELOPMENT; 4.1. Proposed Models for Microbiota-induced Carcinogenesis; 4.2. Antibacteria-Specific Immune Response and Cancer Promotion; 5. MICROBIOTA AND GI CANCERS. | |
| 505 | 8 | |a 5.1. Gut Bacteria Dysbiosis Associated with GI Cancer5.2. Microbiota Involvement in Gastric and Esophageal Cancers, the Role of Helicobacter pylori; 5.3. Microbiota Involvement in Colorectal Cancer; 5.3.1. Specific Gut Bacteria and CRC; 5.3.2. Bacteria Metabolites and CRC; 5.4. Gallbladder Cancer; 5.5. Liver Cancer; 5.6. Pancreatic Cancer; 6. BENEFICIAL ACTIVITIES OF GUT MICROBIOTA; 6.1. Antitumorigenic Impact of Microbiota; 6.2. Manipulating the Microbiota for Cancer Therapy; 7. CONCLUSION; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES. | |
| 505 | 8 | |a Towards Host Cell-Targeting Therapies to Treat Dengue Virus InfectionsCybele C. García1,2, Verónica M. Quintana1, Viviana Castilla1 and Elsa B. Damonte1,2,*; INTRODUCTION; INTERACTION WITH CELL RECEPTORS; ENDOCYTOSIS AND FUSION FOR UNCOATING; LIPID METABOLISM; PROTEIN TRANSLATION; UNFOLDED PROTEIN RESPONSE; UBIQUITIN PROTEASOME PATHWAY; NUCLEOTIDE METABOLISM; KINASES; Mitogen-activated Protein Kinases; ERK Pathway; JNK Pathway; p38 Pathway; Other Kinases; Src, Ab1 and Fyn Kinases; AP2-associated Protein Kinase 1 and Cyclin G-associated Kinase; Phosphatidylinositol 3 Kinase/Akt Pathway. | |
| 505 | 8 | |a SCREENING STRATEGIES TO CHARACTERISE PLANT PRODUCTS WITH POTENTIAL RESISTANCE MODIFYING ACTIVITYASSESSMENT OF SYNERGISTIC INTERACTION BETWEEN ANTIBIOTIC AND A PHYTOCOMPOUND AGAINST RESISTANT BACTERIA; Fractional Inhibitory Concentration Index (FICI); Modulation Factor (MF); Isobologram; SEARCH FOR PLANT-DERIVED SECONDARY METABOLITES WITH PROSPECTIVE RESISTANCE MODIFYING ACTIVITY; Key Early Studies Pertaining to Discovery of RMAs from Plants; Recent Studies; PHYTOCHEMICALS AND RELEVANT BACTERIAL RESISTANCE MECHANISMS; Efflux Pump Inhibition; Alteration of Bacterial Cell Membrane Permeability. | |
| 500 | |a Protein Synthesis Inhibition. | ||
| 650 | 0 | |a Anti-infective agents. |0 http://id.loc.gov/authorities/subjects/sh85005613 | |
| 650 | 0 | |a Communicable diseases. |0 http://id.loc.gov/authorities/subjects/sh85029015 | |
| 650 | 2 | |a Anti-Infective Agents |0 https://id.nlm.nih.gov/mesh/D000890 | |
| 650 | 2 | |a Communicable Diseases |0 https://id.nlm.nih.gov/mesh/D003141 | |
| 650 | 6 | |a Antiinfectieux. | |
| 650 | 6 | |a Maladies infectieuses. | |
| 650 | 7 | |a Anti-infective agents |2 fast | |
| 650 | 7 | |a Communicable diseases |2 fast | |
| 700 | 1 | |a Chaudhry, Iqbal. | |
| 758 | |i has work: |a Frontiers in Anti-Infective Drug Discovery (Text) |1 https://id.oclc.org/worldcat/entity/E39PD3v3qdvhcpmxCDmwvpXtDq |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Atta-ur-Rehman. |t Frontiers in Anti-Infective Drug Discovery: Volume 7. |d Sharjah : Bentham Science Publishers, ©2018 |z 9781681085630 |
| 830 | 0 | |a Frontiers in Anti-Infective Drug Discovery Ser. | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1828652 |3 Volltext |
| 880 | 8 | |6 505-01/(S |a PROTEIN PROCESSINGEndoplasmic Reticulum α-glucosidases; Furin; Endoplasmic Reticulum Associated Signal Peptidase; INNATE ANTIVIRAL RESPONSE; Interferon Activity; Cell-intrinsic Restriction Factors; CONCLUDING REMARKS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Synergistic Interaction Between Plant Products and Antibiotics Against Potential Pathogenic Bacteria; Banasri Hazra1,*, Sutapa Biswas Majee2, Subhalakshmi Ghosh1 and Dhruti Avlani2; INTRODUCTION; BACTERIAL RESISTANCE TOWARDS CLINICAL ANTIBIOTICS; Background; Mechanisms and Associated Factors. | |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL5430376 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH37581022 | ||
| 938 | |a YBP Library Services |b YANK |n 15535280 | ||
| 938 | |a EBSCOhost |b EBSC |n 1828652 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1041918857 |
|---|---|
| _version_ | 1816882463596609536 |
| adam_text | |
| any_adam_object | |
| author | Atta-ur-Rehman |
| author2 | Chaudhry, Iqbal |
| author2_role | |
| author2_variant | i c ic |
| author_facet | Atta-ur-Rehman Chaudhry, Iqbal |
| author_role | |
| author_sort | Atta-ur-Rehman |
| author_variant | a u au |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM267 |
| callnumber-raw | RM267 |
| callnumber-search | RM267 |
| callnumber-sort | RM 3267 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | Intro; CONTENTS; PREFACE; List of Contributors; The Role of the Microbiota in the Genesis of Gastrointestinal Cancers; Edda Russo and Amedeo Amedei*; 1. INTRODUCTION; 2. THE HUMAN MICROBIOTA; 3. THE GASTROINTESTINAL MICROBIOTA; 3.1. Composition and Activities; 3.2. Gastro-Intestinal Colonization by the Microbiota and Selection; 3.3. The Human Microbiome Project; 3.4. Gut Enterotypes; 4. THE ROLE OF MICROBIOTA IN TUMOR DEVELOPMENT; 4.1. Proposed Models for Microbiota-induced Carcinogenesis; 4.2. Antibacteria-Specific Immune Response and Cancer Promotion; 5. MICROBIOTA AND GI CANCERS. 5.1. Gut Bacteria Dysbiosis Associated with GI Cancer5.2. Microbiota Involvement in Gastric and Esophageal Cancers, the Role of Helicobacter pylori; 5.3. Microbiota Involvement in Colorectal Cancer; 5.3.1. Specific Gut Bacteria and CRC; 5.3.2. Bacteria Metabolites and CRC; 5.4. Gallbladder Cancer; 5.5. Liver Cancer; 5.6. Pancreatic Cancer; 6. BENEFICIAL ACTIVITIES OF GUT MICROBIOTA; 6.1. Antitumorigenic Impact of Microbiota; 6.2. Manipulating the Microbiota for Cancer Therapy; 7. CONCLUSION; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES. Towards Host Cell-Targeting Therapies to Treat Dengue Virus InfectionsCybele C. García1,2, Verónica M. Quintana1, Viviana Castilla1 and Elsa B. Damonte1,2,*; INTRODUCTION; INTERACTION WITH CELL RECEPTORS; ENDOCYTOSIS AND FUSION FOR UNCOATING; LIPID METABOLISM; PROTEIN TRANSLATION; UNFOLDED PROTEIN RESPONSE; UBIQUITIN PROTEASOME PATHWAY; NUCLEOTIDE METABOLISM; KINASES; Mitogen-activated Protein Kinases; ERK Pathway; JNK Pathway; p38 Pathway; Other Kinases; Src, Ab1 and Fyn Kinases; AP2-associated Protein Kinase 1 and Cyclin G-associated Kinase; Phosphatidylinositol 3 Kinase/Akt Pathway. SCREENING STRATEGIES TO CHARACTERISE PLANT PRODUCTS WITH POTENTIAL RESISTANCE MODIFYING ACTIVITYASSESSMENT OF SYNERGISTIC INTERACTION BETWEEN ANTIBIOTIC AND A PHYTOCOMPOUND AGAINST RESISTANT BACTERIA; Fractional Inhibitory Concentration Index (FICI); Modulation Factor (MF); Isobologram; SEARCH FOR PLANT-DERIVED SECONDARY METABOLITES WITH PROSPECTIVE RESISTANCE MODIFYING ACTIVITY; Key Early Studies Pertaining to Discovery of RMAs from Plants; Recent Studies; PHYTOCHEMICALS AND RELEVANT BACTERIAL RESISTANCE MECHANISMS; Efflux Pump Inhibition; Alteration of Bacterial Cell Membrane Permeability. |
| ctrlnum | (OCoLC)1041918857 |
| dewey-full | 616.9/0461 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.9/0461 |
| dewey-search | 616.9/0461 |
| dewey-sort | 3616.9 3461 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05390cam a2200601Mu 4500</leader><controlfield tag="001">ZDB-4-EBA-on1041918857</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |n|---|||||</controlfield><controlfield tag="008">180623s2018 xx o 000 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">EBLCP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCF</subfield><subfield code="d">YDX</subfield><subfield code="d">N$T</subfield><subfield code="d">UKAHL</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="066" ind1=" " ind2=" "><subfield code="c">(S</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">1040624054</subfield><subfield code="a">1264792542</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781681085623</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1681085623</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1041918857</subfield><subfield code="z">(OCoLC)1040624054</subfield><subfield code="z">(OCoLC)1264792542</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM267</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.9/0461</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Atta-ur-Rehman.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Frontiers in Anti-Infective Drug Discovery.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Sharjah :</subfield><subfield code="b">Bentham Science Publishers,</subfield><subfield code="c">2018.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (293 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers in Anti-Infective Drug Discovery Ser. ;</subfield><subfield code="v">v. 7</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="6">880-01</subfield><subfield code="a">Intro; CONTENTS; PREFACE; List of Contributors; The Role of the Microbiota in the Genesis of Gastrointestinal Cancers; Edda Russo and Amedeo Amedei*; 1. INTRODUCTION; 2. THE HUMAN MICROBIOTA; 3. THE GASTROINTESTINAL MICROBIOTA; 3.1. Composition and Activities; 3.2. Gastro-Intestinal Colonization by the Microbiota and Selection; 3.3. The Human Microbiome Project; 3.4. Gut Enterotypes; 4. THE ROLE OF MICROBIOTA IN TUMOR DEVELOPMENT; 4.1. Proposed Models for Microbiota-induced Carcinogenesis; 4.2. Antibacteria-Specific Immune Response and Cancer Promotion; 5. MICROBIOTA AND GI CANCERS.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">5.1. Gut Bacteria Dysbiosis Associated with GI Cancer5.2. Microbiota Involvement in Gastric and Esophageal Cancers, the Role of Helicobacter pylori; 5.3. Microbiota Involvement in Colorectal Cancer; 5.3.1. Specific Gut Bacteria and CRC; 5.3.2. Bacteria Metabolites and CRC; 5.4. Gallbladder Cancer; 5.5. Liver Cancer; 5.6. Pancreatic Cancer; 6. BENEFICIAL ACTIVITIES OF GUT MICROBIOTA; 6.1. Antitumorigenic Impact of Microbiota; 6.2. Manipulating the Microbiota for Cancer Therapy; 7. CONCLUSION; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Towards Host Cell-Targeting Therapies to Treat Dengue Virus InfectionsCybele C. García1,2, Verónica M. Quintana1, Viviana Castilla1 and Elsa B. Damonte1,2,*; INTRODUCTION; INTERACTION WITH CELL RECEPTORS; ENDOCYTOSIS AND FUSION FOR UNCOATING; LIPID METABOLISM; PROTEIN TRANSLATION; UNFOLDED PROTEIN RESPONSE; UBIQUITIN PROTEASOME PATHWAY; NUCLEOTIDE METABOLISM; KINASES; Mitogen-activated Protein Kinases; ERK Pathway; JNK Pathway; p38 Pathway; Other Kinases; Src, Ab1 and Fyn Kinases; AP2-associated Protein Kinase 1 and Cyclin G-associated Kinase; Phosphatidylinositol 3 Kinase/Akt Pathway.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">SCREENING STRATEGIES TO CHARACTERISE PLANT PRODUCTS WITH POTENTIAL RESISTANCE MODIFYING ACTIVITYASSESSMENT OF SYNERGISTIC INTERACTION BETWEEN ANTIBIOTIC AND A PHYTOCOMPOUND AGAINST RESISTANT BACTERIA; Fractional Inhibitory Concentration Index (FICI); Modulation Factor (MF); Isobologram; SEARCH FOR PLANT-DERIVED SECONDARY METABOLITES WITH PROSPECTIVE RESISTANCE MODIFYING ACTIVITY; Key Early Studies Pertaining to Discovery of RMAs from Plants; Recent Studies; PHYTOCHEMICALS AND RELEVANT BACTERIAL RESISTANCE MECHANISMS; Efflux Pump Inhibition; Alteration of Bacterial Cell Membrane Permeability.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Protein Synthesis Inhibition.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Anti-infective agents.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85005613</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Communicable diseases.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85029015</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Anti-Infective Agents</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D000890</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Communicable Diseases</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D003141</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Antiinfectieux.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Maladies infectieuses.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-infective agents</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Communicable diseases</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chaudhry, Iqbal.</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Frontiers in Anti-Infective Drug Discovery (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PD3v3qdvhcpmxCDmwvpXtDq</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Atta-ur-Rehman.</subfield><subfield code="t">Frontiers in Anti-Infective Drug Discovery: Volume 7.</subfield><subfield code="d">Sharjah : Bentham Science Publishers, ©2018</subfield><subfield code="z">9781681085630</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Frontiers in Anti-Infective Drug Discovery Ser.</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1828652</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="880" ind1="8" ind2=" "><subfield code="6">505-01/(S</subfield><subfield code="a">PROTEIN PROCESSINGEndoplasmic Reticulum α-glucosidases; Furin; Endoplasmic Reticulum Associated Signal Peptidase; INNATE ANTIVIRAL RESPONSE; Interferon Activity; Cell-intrinsic Restriction Factors; CONCLUDING REMARKS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Synergistic Interaction Between Plant Products and Antibiotics Against Potential Pathogenic Bacteria; Banasri Hazra1,*, Sutapa Biswas Majee2, Subhalakshmi Ghosh1 and Dhruti Avlani2; INTRODUCTION; BACTERIAL RESISTANCE TOWARDS CLINICAL ANTIBIOTICS; Background; Mechanisms and Associated Factors.</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL5430376</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH37581022</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">15535280</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1828652</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1041918857 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:29:01Z |
| institution | BVB |
| isbn | 9781681085623 1681085623 |
| language | English |
| oclc_num | 1041918857 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (293 pages) |
| psigel | ZDB-4-EBA |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | Bentham Science Publishers, |
| record_format | marc |
| series | Frontiers in Anti-Infective Drug Discovery Ser. |
| series2 | Frontiers in Anti-Infective Drug Discovery Ser. ; |
| spelling | Atta-ur-Rehman. Frontiers in Anti-Infective Drug Discovery. Sharjah : Bentham Science Publishers, 2018. 1 online resource (293 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers in Anti-Infective Drug Discovery Ser. ; v. 7 Print version record. 880-01 Intro; CONTENTS; PREFACE; List of Contributors; The Role of the Microbiota in the Genesis of Gastrointestinal Cancers; Edda Russo and Amedeo Amedei*; 1. INTRODUCTION; 2. THE HUMAN MICROBIOTA; 3. THE GASTROINTESTINAL MICROBIOTA; 3.1. Composition and Activities; 3.2. Gastro-Intestinal Colonization by the Microbiota and Selection; 3.3. The Human Microbiome Project; 3.4. Gut Enterotypes; 4. THE ROLE OF MICROBIOTA IN TUMOR DEVELOPMENT; 4.1. Proposed Models for Microbiota-induced Carcinogenesis; 4.2. Antibacteria-Specific Immune Response and Cancer Promotion; 5. MICROBIOTA AND GI CANCERS. 5.1. Gut Bacteria Dysbiosis Associated with GI Cancer5.2. Microbiota Involvement in Gastric and Esophageal Cancers, the Role of Helicobacter pylori; 5.3. Microbiota Involvement in Colorectal Cancer; 5.3.1. Specific Gut Bacteria and CRC; 5.3.2. Bacteria Metabolites and CRC; 5.4. Gallbladder Cancer; 5.5. Liver Cancer; 5.6. Pancreatic Cancer; 6. BENEFICIAL ACTIVITIES OF GUT MICROBIOTA; 6.1. Antitumorigenic Impact of Microbiota; 6.2. Manipulating the Microbiota for Cancer Therapy; 7. CONCLUSION; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES. Towards Host Cell-Targeting Therapies to Treat Dengue Virus InfectionsCybele C. García1,2, Verónica M. Quintana1, Viviana Castilla1 and Elsa B. Damonte1,2,*; INTRODUCTION; INTERACTION WITH CELL RECEPTORS; ENDOCYTOSIS AND FUSION FOR UNCOATING; LIPID METABOLISM; PROTEIN TRANSLATION; UNFOLDED PROTEIN RESPONSE; UBIQUITIN PROTEASOME PATHWAY; NUCLEOTIDE METABOLISM; KINASES; Mitogen-activated Protein Kinases; ERK Pathway; JNK Pathway; p38 Pathway; Other Kinases; Src, Ab1 and Fyn Kinases; AP2-associated Protein Kinase 1 and Cyclin G-associated Kinase; Phosphatidylinositol 3 Kinase/Akt Pathway. SCREENING STRATEGIES TO CHARACTERISE PLANT PRODUCTS WITH POTENTIAL RESISTANCE MODIFYING ACTIVITYASSESSMENT OF SYNERGISTIC INTERACTION BETWEEN ANTIBIOTIC AND A PHYTOCOMPOUND AGAINST RESISTANT BACTERIA; Fractional Inhibitory Concentration Index (FICI); Modulation Factor (MF); Isobologram; SEARCH FOR PLANT-DERIVED SECONDARY METABOLITES WITH PROSPECTIVE RESISTANCE MODIFYING ACTIVITY; Key Early Studies Pertaining to Discovery of RMAs from Plants; Recent Studies; PHYTOCHEMICALS AND RELEVANT BACTERIAL RESISTANCE MECHANISMS; Efflux Pump Inhibition; Alteration of Bacterial Cell Membrane Permeability. Protein Synthesis Inhibition. Anti-infective agents. http://id.loc.gov/authorities/subjects/sh85005613 Communicable diseases. http://id.loc.gov/authorities/subjects/sh85029015 Anti-Infective Agents https://id.nlm.nih.gov/mesh/D000890 Communicable Diseases https://id.nlm.nih.gov/mesh/D003141 Antiinfectieux. Maladies infectieuses. Anti-infective agents fast Communicable diseases fast Chaudhry, Iqbal. has work: Frontiers in Anti-Infective Drug Discovery (Text) https://id.oclc.org/worldcat/entity/E39PD3v3qdvhcpmxCDmwvpXtDq https://id.oclc.org/worldcat/ontology/hasWork Print version: Atta-ur-Rehman. Frontiers in Anti-Infective Drug Discovery: Volume 7. Sharjah : Bentham Science Publishers, ©2018 9781681085630 Frontiers in Anti-Infective Drug Discovery Ser. FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1828652 Volltext 505-01/(S PROTEIN PROCESSINGEndoplasmic Reticulum α-glucosidases; Furin; Endoplasmic Reticulum Associated Signal Peptidase; INNATE ANTIVIRAL RESPONSE; Interferon Activity; Cell-intrinsic Restriction Factors; CONCLUDING REMARKS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Synergistic Interaction Between Plant Products and Antibiotics Against Potential Pathogenic Bacteria; Banasri Hazra1,*, Sutapa Biswas Majee2, Subhalakshmi Ghosh1 and Dhruti Avlani2; INTRODUCTION; BACTERIAL RESISTANCE TOWARDS CLINICAL ANTIBIOTICS; Background; Mechanisms and Associated Factors. |
| spellingShingle | Atta-ur-Rehman Frontiers in Anti-Infective Drug Discovery. Frontiers in Anti-Infective Drug Discovery Ser. Intro; CONTENTS; PREFACE; List of Contributors; The Role of the Microbiota in the Genesis of Gastrointestinal Cancers; Edda Russo and Amedeo Amedei*; 1. INTRODUCTION; 2. THE HUMAN MICROBIOTA; 3. THE GASTROINTESTINAL MICROBIOTA; 3.1. Composition and Activities; 3.2. Gastro-Intestinal Colonization by the Microbiota and Selection; 3.3. The Human Microbiome Project; 3.4. Gut Enterotypes; 4. THE ROLE OF MICROBIOTA IN TUMOR DEVELOPMENT; 4.1. Proposed Models for Microbiota-induced Carcinogenesis; 4.2. Antibacteria-Specific Immune Response and Cancer Promotion; 5. MICROBIOTA AND GI CANCERS. 5.1. Gut Bacteria Dysbiosis Associated with GI Cancer5.2. Microbiota Involvement in Gastric and Esophageal Cancers, the Role of Helicobacter pylori; 5.3. Microbiota Involvement in Colorectal Cancer; 5.3.1. Specific Gut Bacteria and CRC; 5.3.2. Bacteria Metabolites and CRC; 5.4. Gallbladder Cancer; 5.5. Liver Cancer; 5.6. Pancreatic Cancer; 6. BENEFICIAL ACTIVITIES OF GUT MICROBIOTA; 6.1. Antitumorigenic Impact of Microbiota; 6.2. Manipulating the Microbiota for Cancer Therapy; 7. CONCLUSION; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES. Towards Host Cell-Targeting Therapies to Treat Dengue Virus InfectionsCybele C. García1,2, Verónica M. Quintana1, Viviana Castilla1 and Elsa B. Damonte1,2,*; INTRODUCTION; INTERACTION WITH CELL RECEPTORS; ENDOCYTOSIS AND FUSION FOR UNCOATING; LIPID METABOLISM; PROTEIN TRANSLATION; UNFOLDED PROTEIN RESPONSE; UBIQUITIN PROTEASOME PATHWAY; NUCLEOTIDE METABOLISM; KINASES; Mitogen-activated Protein Kinases; ERK Pathway; JNK Pathway; p38 Pathway; Other Kinases; Src, Ab1 and Fyn Kinases; AP2-associated Protein Kinase 1 and Cyclin G-associated Kinase; Phosphatidylinositol 3 Kinase/Akt Pathway. SCREENING STRATEGIES TO CHARACTERISE PLANT PRODUCTS WITH POTENTIAL RESISTANCE MODIFYING ACTIVITYASSESSMENT OF SYNERGISTIC INTERACTION BETWEEN ANTIBIOTIC AND A PHYTOCOMPOUND AGAINST RESISTANT BACTERIA; Fractional Inhibitory Concentration Index (FICI); Modulation Factor (MF); Isobologram; SEARCH FOR PLANT-DERIVED SECONDARY METABOLITES WITH PROSPECTIVE RESISTANCE MODIFYING ACTIVITY; Key Early Studies Pertaining to Discovery of RMAs from Plants; Recent Studies; PHYTOCHEMICALS AND RELEVANT BACTERIAL RESISTANCE MECHANISMS; Efflux Pump Inhibition; Alteration of Bacterial Cell Membrane Permeability. Anti-infective agents. http://id.loc.gov/authorities/subjects/sh85005613 Communicable diseases. http://id.loc.gov/authorities/subjects/sh85029015 Anti-Infective Agents https://id.nlm.nih.gov/mesh/D000890 Communicable Diseases https://id.nlm.nih.gov/mesh/D003141 Antiinfectieux. Maladies infectieuses. Anti-infective agents fast Communicable diseases fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85005613 http://id.loc.gov/authorities/subjects/sh85029015 https://id.nlm.nih.gov/mesh/D000890 https://id.nlm.nih.gov/mesh/D003141 |
| title | Frontiers in Anti-Infective Drug Discovery. |
| title_auth | Frontiers in Anti-Infective Drug Discovery. |
| title_exact_search | Frontiers in Anti-Infective Drug Discovery. |
| title_full | Frontiers in Anti-Infective Drug Discovery. |
| title_fullStr | Frontiers in Anti-Infective Drug Discovery. |
| title_full_unstemmed | Frontiers in Anti-Infective Drug Discovery. |
| title_short | Frontiers in Anti-Infective Drug Discovery. |
| title_sort | frontiers in anti infective drug discovery |
| topic | Anti-infective agents. http://id.loc.gov/authorities/subjects/sh85005613 Communicable diseases. http://id.loc.gov/authorities/subjects/sh85029015 Anti-Infective Agents https://id.nlm.nih.gov/mesh/D000890 Communicable Diseases https://id.nlm.nih.gov/mesh/D003141 Antiinfectieux. Maladies infectieuses. Anti-infective agents fast Communicable diseases fast |
| topic_facet | Anti-infective agents. Communicable diseases. Anti-Infective Agents Communicable Diseases Antiinfectieux. Maladies infectieuses. Anti-infective agents Communicable diseases |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1828652 |
| work_keys_str_mv | AT attaurrehman frontiersinantiinfectivedrugdiscovery AT chaudhryiqbal frontiersinantiinfectivedrugdiscovery |